Posted in:

Hemispherx ramps up Ampligen price by 267%

Hemispherx has unexpectedly ramped up the price of Ampligen by 267%, from $15,600 to $41,600 per year, effective immediately as of July 24, 2015, according to trial patient reports. Jeannette Burmeister has written to Dr. Janet Woodcock, the FDA’s Director of the Center for Drug Evaluation and Research, voicing grave concerns for patients in Hemispherx’s AMP-511 open-label clinical trial.


Written by Russell Logan


Russell Logan worked as a magazine publisher and editor until forced into early retirement through ill health with ME. He has battled with moderate to severe ME for 25 years. He now lives in Noosaville, Australia.

87 posts

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.